We evaluated the impact of opioid substitution therapy (OST) on the completion, adherence, efficacy, and safety of the 3-direct-acting antiviral regimen of ombitasvir, paritaprevir (identified by AbbVie and Enanta) co-dosed with ritonavir, and dasabuvir ± ribavirin among patients infected with hepatitis C virus (HCV) genotype (GT) 1, with or without compensated cirrhosis.

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials / Grebely, J., Puoti, M., Wedemeyer, H., Cooper, C., Sulkowski, M.S., Foster, G.R., Berg, T., Villa, E., Rodriguez-Perez, F., Wyles, D.L., Schnell, G., Alami, N.N., Zhang, Z., Dumas, E., Dore, G.J.. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 5:11(2018), pp. ofy248-ofy248. [10.1093/ofid/ofy248]

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials

Villa, Erica;
2018

Abstract

We evaluated the impact of opioid substitution therapy (OST) on the completion, adherence, efficacy, and safety of the 3-direct-acting antiviral regimen of ombitasvir, paritaprevir (identified by AbbVie and Enanta) co-dosed with ritonavir, and dasabuvir ± ribavirin among patients infected with hepatitis C virus (HCV) genotype (GT) 1, with or without compensated cirrhosis.
2018
5
11
ofy248
ofy248
WOS:000457594300008
2-s2.0-85061012326
30430131
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials / Grebely, J., Puoti, M., Wedemeyer, H., Cooper, C., Sulkowski, M.S., Foster, G.R., Berg, T., Villa, E., Rodriguez-Perez, F., Wyles, D.L., Schnell, G., Alami, N.N., Zhang, Z., Dumas, E., Dore, G.J.. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 5:11(2018), pp. ofy248-ofy248. [10.1093/ofid/ofy248]
Grebely, Jason; Puoti, Massimo; Wedemeyer, Heiner; Cooper, Curtis; Sulkowski, Mark S; Foster, Graham R; Berg, Thomas; Villa, Erica; Rodriguez-Perez, F...espandi
File in questo prodotto:
File Dimensione Formato  
ofy248.pdf

Open access

Tipologia: VOR - Versione pubblicata dall'editore
Licenza: [IR] creative-commons
Dimensione 194.8 kB
Formato Adobe PDF
Visualizza/Apri
194.8 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1167679
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact